We are live on ! Find out more
FUSN

Fusion Pharmaceuticals Inc. Common Shares
FUSN

Delisted

FUSN was delisted on the 3rd of June, 2024.

Back to rankings

114 hedge funds and large institutions have $1.47B invested in Fusion Pharmaceuticals Inc. Common Shares in 2024 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 24 increasing their positions, 14 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more funds holding in top 10

Funds holding in top 10: 3 → 8 (+5)

151% more capital invested

Capital invested by funds: $586M → $1.47B (+$887M)

132% more first-time investments, than exits

New positions opened: 65 | Existing positions closed: 28

71% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 14

48% more funds holding

Funds holding: 77 → 114 (+37)

43% less call options, than puts

Call options by funds: $48M | Put options by funds: $84.2M

Holders
114
Holders Change
+37
Holders Change %
+48.05%
% of All Funds
1.64%
Holding in Top 10
8
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+166.67%
% of All Funds
0.12%
New
65
Increased
24
Reduced
14
Closed
28
Calls
$48M
Puts
$84.2M
Net Calls
-$36.2M
Net Calls Change
-$36.7M

Top Buyers

Rank Fund Capital Flow
1
Fidelity International
Fidelity International
Bermuda
+$50.1M
2
PA
Perceptive Advisors
New York
+$48.7M
3
PCM
Pentwater Capital Management
Florida
+$45.2M
4
Marshall Wace
Marshall Wace
United Kingdom
+$14.1M
5
Millennium Management
Millennium Management
New York
+$12.3M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$41.6M
2
O
OrbiMed
New York
-$30M
3
ASP
Adams Street Partners
Illinois
-$28.3M
4
PBPIA
Pivotal bioVenture Partners Investment Advisor
California
-$11.9M
5
AG
Artal Group
Luxembourg
-$9.66M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
26
Citadel Advisors
Florida
$10.1M +$5.01M +419,253 +775%
SFM
27
Sphera Funds Management
Israel
$9.57M -$7.61M -636,598 -59%
Verition Fund Management
28
Verition Fund Management
Connecticut
$8.78M +$3.62M +302,648 +277%
DFO
29
Duquesne Family Office
New York
$8.52M +$4.78M +399,748 New
Two Sigma Investments
30
Two Sigma Investments
New York
$7.51M +$2.79M +233,552 +196%
Morgan Stanley
31
Morgan Stanley
New York
$6.35M -$1.39M -116,352 -28%
TI
32
Trexquant Investment
Connecticut
$6.05M +$3.4M +283,926 New
OAC
33
OMERS Administration Corp
Ontario, Canada
$5.89M +$3.31M +276,400 New
PFM
34
Privium Fund Management
Netherlands
$5.35M +$1.31M +109,408 +77%
SCM
35
Sio Capital Management
New York
$5.18M -$35.9K -3,001 -1%
ACM
36
Atika Capital Management
New York
$4.97M +$1.23M +102,600 +79%
ACM
37
ADAR1 Capital Management
Texas
$3.78M +$2.12M +177,200 New
CCM
38
Chicago Capital Management
Illinois
$3.63M +$2.04M +170,200 New
FAM
39
Fred Alger Management
New York
$3.57M -$1.73M -144,559 -46%
Hudson Bay Capital Management
40
Hudson Bay Capital Management
Connecticut
$3.52M +$1.97M +165,000 New
Axa
41
Axa
France
$3.51M +$1.97M +164,521 New
SI
42
Sofinnova Investments
California
$3.35M +$381K +31,873 +25%
MCP
43
Maso Capital Partners
Hong Kong
$3.2M +$1.79M +150,000 New
Susquehanna International Group
44
Susquehanna International Group
Pennsylvania
$3.15M +$1.54M +129,082 +699%
GF
45
Gabelli Funds
New York
$3.12M +$1.75M +146,150 New
HP
46
HealthInvest Partners
Sweden
$2.96M +$165K +13,836 +11%
HM
47
Harvest Management
New York
$2.56M +$1.44M +120,000 New
GCIA
48
Gabelli & Co Investment Advisers
New York
$2.47M +$1.38M +115,750 New
FTCM
49
First Trust Capital Management
Illinois
$2.3M +$1.29M +107,737 New
PCM
50
Prelude Capital Management
New York
$2.2M +$1.24M +103,298 New
1
2
3 4 5

FUSN Hedge Fund Activity: Q1 2024 in Review

114 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q1 2024, worth a combined $1.47B — up 151% from $586M a quarter earlier.

Buyers outnumbered sellers: 65 funds opened new FUSN positions and 28 closed out — a net gain of 37 holders — while 24 added to existing stakes and 14 trimmed.

The largest buyer was Fidelity International, opening a new position worth an estimated $50.1M. The largest seller was Fidelity Investments, cutting an estimated $41.6M.

  • 114 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q1 2024, up from 77 in Q4 2023.
  • Funds reported $1.47B of Fusion Pharmaceuticals Inc. Common Shares stock for Q1 2024, up 151% quarter-over-quarter.
  • 65 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q1 2024 and 28 closed out, a net change of +37 holders.
  • The largest Fusion Pharmaceuticals Inc. Common Shares buyer in Q1 2024 was Fidelity International, an estimated $50.1M added.
  • The largest Fusion Pharmaceuticals Inc. Common Shares seller in Q1 2024 was Fidelity Investments, an estimated $41.6M sold.

Based on aggregated 13F filings for Q1 2024.